ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc (RCKT)

23.59
0.24
(1.03%)
Closed July 17 4:00PM
23.59
0.00
( 0.00% )
Pre Market: 7:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

RCKT News

Official News Only

RCKT Discussion

View Posts
Monksdream Monksdream 7 months ago
RCKT new 52 week high
👍️0
make it happen make it happen 10 months ago
How's it up 38% @ $21.00 PPS when diluting $175,000,000 million @ $16.00??
👍️0
trkyhntr trkyhntr 4 years ago
I have been away at hunting camp for a few weeks, and when I got back I was pleasantly surprised. This puppy has doubled! Any thoughts as to how much more upside there is?
👍️0
ClayTrader ClayTrader 4 years ago
* * $RCKT Video Chart 12-09-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Glider549 Glider549 4 years ago
Check out Seeking Alpha, January 27, article.
Lots of insider buying and Fast Track status.
👍️0
RUSTYJ RUSTYJ 5 years ago
How you figure a lot power , Gravity takes it down
👍️0
investor86 investor86 6 years ago
This got a lot of power!!
👍️0
trkyhntr trkyhntr 6 years ago
This is a new board for this stock. Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
👍️0

Your Recent History

Delayed Upgrade Clock